Literature DB >> 31431443

Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.

Harshvardhan Upreti1,2, Jamil Kasmani1, Kathryn Dane3, Evan M Braunstein1, Michael B Streiff1, Satish Shanbhag1, Alison R Moliterno1, C John Sperati4, Rebecca F Gottesman5, Robert A Brodsky1, Thomas S Kickler6, Shruti Chaturvedi1.   

Abstract

With timely and effective treatment, most patients with thrombotic thrombocytopenic purpura (TTP) survive the acute TTP episode. In addition to the risk of relapse, TTP survivors have higher all-cause mortality than the general population and increased rates of chronic morbidities, including hypertension, depression, and mild cognitive impairment. We conducted this retrospective-prospective cohort study to determine the incidence and prevalence of stroke after recovery from acute TTP and to test the hypothesis that lower ADAMTS13 activity after recovery from TTP is associated with an increased risk of stroke during remission. Of 170 consecutive patients treated for TTP at The Johns Hopkins Hospital from 1995 through 2018, 14 (8.2%) died during the index episode and 19 were observed for less than 1 month after recovery. Of the remaining 137 patients, 18 (13.1%) developed stroke unrelated to an acute TTP episode over a median observation period of 3.08 years, which is fivefold higher than the expected prevalence of 2.6% from an age- and sex-matched reference population (P = .002). ADAMTS13 activity during remission was measured in 52 patients and was >70% in 44.2%, 40% to 70% in 23.1%, 10% to 39% in 25%, and <10% in 7.7%. Stroke after recovery from acute TTP occurred in 0% (0 of 22) of patients with normal remission ADAMTS13 activity (>70%) and in 27.6% (8 of 29) of patients with low ADAMTS13 activity (≤70%; P = .007). In conclusion, stroke is common after recovery from TTP and is associated with reduced ADAMTS13 activity during remission.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31431443      PMCID: PMC7022317          DOI: 10.1182/blood.2019001056

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.

Authors:  Haochen Xu; Yongliang Cao; Xing Yang; Ping Cai; Lijing Kang; Ximin Zhu; Haiyu Luo; Lu Lu; Lixiang Wei; Xiaofei Bai; Yuanbo Zhu; Bing-Qiao Zhao; Wenying Fan
Journal:  Blood       Date:  2017-04-20       Impact factor: 22.113

2.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

3.  Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Marie A Scully; James Paskavitz; Paul Maruff; Leslie Witkoff; Ming Jin; Nicholas Uva; James C Gilbert; Haifeng M Wu
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

4.  ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion.

Authors:  Masayuki Fujioka; Kazuhide Hayakawa; Kenichi Mishima; Ai Kunizawa; Keiichi Irie; Sei Higuchi; Takafumi Nakano; Carl Muroi; Hidetada Fukushima; Mitsuhiko Sugimoto; Fumiaki Banno; Koichi Kokame; Toshiyuki Miyata; Michihiro Fujiwara; Kazuo Okuchi; Kenji Nishio
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

5.  Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.

Authors:  Takafumi Nakano; Keiichi Irie; Kazuhide Hayakawa; Kazunori Sano; Yoshihiko Nakamura; Masayoshi Tanaka; Yuta Yamashita; Tomomitsu Satho; Masayuki Fujioka; Carl Muroi; Koichi Matsuo; Hiroyasu Ishikura; Kojiro Futagami; Kenichi Mishima
Journal:  Brain Res       Date:  2015-08-05       Impact factor: 3.252

Review 6.  Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.

Authors:  Nancy Turner; Leticia Nolasco; Jennifer Nolasco; Sarah Sartain; Joel Moake
Journal:  Semin Thromb Hemost       Date:  2014-06-26       Impact factor: 4.180

7.  Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study.

Authors:  Rohit R Das; Sudha Seshadri; Alexa S Beiser; Margaret Kelly-Hayes; Rhoda Au; Jayandra J Himali; Carlos S Kase; Emelia J Benjamin; Joseph F Polak; Christopher J O'Donnell; Mitsuhiro Yoshita; Ralph B D'Agostino; Charles DeCarli; Philip A Wolf
Journal:  Stroke       Date:  2008-06-26       Impact factor: 7.914

8.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

9.  Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura.

Authors:  Shruti Chaturvedi; Hashim Abbas; Keith R McCrae
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

10.  Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients.

Authors:  T N Bongers; E L E de Bruijne; D W J Dippel; A J de Jong; J W Deckers; D Poldermans; M P M de Maat; F W G Leebeek
Journal:  Atherosclerosis       Date:  2009-04-17       Impact factor: 5.162

View more
  14 in total

1.  Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia.

Authors:  Azra Borogovac; James N George
Journal:  Blood Adv       Date:  2019-12-10

2.  Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Max A Brodsky; Senthil Sukumar; Sruthi Selvakumar; Lisa Yanek; Sarah Hussain; Marshall A Mazepa; Evan M Braunstein; Alison R Moliterno; Thomas S Kickler; Robert A Brodsky; Spero R Cataland; Shruti Chaturvedi
Journal:  Am J Hematol       Date:  2021-09-15       Impact factor: 10.047

3.  Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?

Authors:  Bojing Shao; Sanober Nusrat; James N George; Lijun Xia
Journal:  Am J Hematol       Date:  2022-06-07       Impact factor: 13.265

Review 4.  Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist.

Authors:  Juliana Perez Botero; Jessica A Reese; James N George; Jennifer J McIntosh
Journal:  Am J Hematol       Date:  2021-09-04       Impact factor: 10.047

5.  ADAMTS proteases in cardiovascular physiology and disease.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Open Biol       Date:  2020-12-23       Impact factor: 6.411

6.  Cerebrovascular manifestations in hematological diseases: an update.

Authors:  José M Ferro; Joana Infante
Journal:  J Neurol       Date:  2021-02-13       Impact factor: 4.849

7.  Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission.

Authors:  Senthil Sukumar; Max Brodsky; Sarah Hussain; Lisa Yanek; Alison Moliterno; Robert Brodsky; Spero R Cataland; Shruti Chaturvedi
Journal:  Blood Adv       Date:  2022-02-22

Review 8.  The standard of care for immune thrombotic thrombocytopenic purpura today.

Authors:  X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-06-30       Impact factor: 16.036

9.  The ADAMTS13-von Willebrand factor axis in COVID-19 patients.

Authors:  Ilaria Mancini; Luciano Baronciani; Andrea Artoni; Paola Colpani; Marina Biganzoli; Giovanna Cozzi; Cristina Novembrino; Massimo Boscolo Anzoletti; Valentina De Zan; Maria Teresa Pagliari; Roberta Gualtierotti; Stefano Aliberti; Mauro Panigada; Giacomo Grasselli; Francesco Blasi; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-12-18       Impact factor: 16.036

10.  Blood-brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study.

Authors:  Shih-Han Susan Huang; Katerina Pavenski; Ting-Yim Lee; Michael T Jurkiewicz; Aditya Bharatha; Jonathan Dale Thiessen; Keith St Lawrence; Jean Théberge; Jennifer Mandzia; David Barth; Christoph Licht; Christopher Jordan Patriquin
Journal:  Blood Adv       Date:  2021-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.